Post-breast cancer, metformin has no effect on mortality

July 3, 2013
Post-breast cancer, metformin has no effect on mortality
For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

(HealthDay)—For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

Iliana C. Lega, M.D., from the Women's College Hospital in Toronto, and colleagues conducted a population-based study involving 2,361 women aged 66 years or older diagnosed with diabetes and . The correlation between cumulative duration of past use and all-cause and breast cancer-specific mortality was assessed.

During a mean follow-up of 4.5 years, the researchers identified 1,101 deaths (46.6 percent), of which 16.3 percent were breast cancer-specific. There was no significant association observed between cumulative duration of past metformin use and all-cause or breast cancer-specific mortality.

"In summary, we conducted a large population-based study to investigate the effects of metformin therapy on mortality after breast cancer in a diabetic population," the authors write. "Cumulative exposure of metformin was not significantly associated with all-cause or breast cancer-specific mortality in our incident diabetic cohort when modeled as a time-varying covariate."

Explore further: Popular diabetes drug does not improve survival rates after cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Screening fails to affect breast cancer mortality statistics

June 11, 2013

New research analysing breast cancer mortality data spanning almost 40 years concludes that breast cancer screening does not yet show an effect on mortality statistics. The research, published in the Journal of the Royal ...

Metformin may have dual effect in breast cancer

May 9, 2012

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects are observed according ...

Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Recommended for you

Research shows nerve growth protein controls blood sugar

November 14, 2016

Research led by a Johns Hopkins University biologist demonstrates the workings of a biochemical pathway that helps control glucose in the bloodstream, a development that could potentially lead to treatments for diabetes.

Researchers discover new regulator in glucose metabolism

November 9, 2016

A key genetic switch in the liver regulates glucose metabolism and insulin action in other organs of the body. Researchers of Helmholtz Zentrum München, in collaboration with colleagues of the Heidelberg University Hospital, ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

talatmahmud
not rated yet Jul 04, 2013
This is as usual informative writing like before on breast cancer. This has helped me to justify the cell division during the breast cancer. I will continue reading with this site on breast cancer. This cancer cell's division is so fast and can spread within a short time for this reason. I have also collected some other information other sites.
Thanks.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.